Sight Sciences, Inc. ((SGHT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Sight Sciences, Inc. is conducting a pilot study titled ‘A Pilot Study of the Helix Surgical System in Subjects With Primary Open-Angle Glaucoma (POAG) and Cataract.’ The study aims to evaluate the safety of the Helix Surgical System during cataract surgery and gather preliminary evidence of its effectiveness in reducing intraocular pressure in patients with mild to moderate POAG and cataracts.
Intervention/Treatment: The study tests the Helix Surgical System, a handheld device designed to viscodilate Schlemm’s canal and collector channels, facilitating an intracanalicular scaffolding procedure to improve the aqueous outflow system in glaucomatous eyes.
Study Design: This interventional study follows a single-group model, conducted as a prospective, single-center, single-arm clinical trial. There is no masking involved, and the primary purpose is treatment.
Study Timeline: The study began on April 21, 2025, with the latest update submitted on July 15, 2025. These dates are crucial as they mark the study’s progression and the most recent data available.
Market Implications: The ongoing study could influence Sight Sciences, Inc.’s stock performance positively if the Helix Surgical System proves effective, potentially enhancing investor confidence. As the company operates in a competitive ophthalmic device market, successful results could position it favorably against competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.